Literature DB >> 31236626

Functions of 'A disintegrin and metalloproteases (ADAMs)' in the mammalian nervous system.

Hung-En Hsia1,2, Johanna Tüshaus1,2, Tobias Brummer1,2, Yuanpeng Zheng1,2, Simone D Scilabra1,2,3, Stefan F Lichtenthaler4,5,6.   

Abstract

'A disintegrin and metalloproteases' (ADAMs) are a family of transmembrane proteins with diverse functions in multicellular organisms. About half of the ADAMs are active metalloproteases and cleave numerous cell surface proteins, including growth factors, receptors, cytokines and cell adhesion proteins. The other ADAMs have no catalytic activity and function as adhesion proteins or receptors. Some ADAMs are ubiquitously expressed, others are expressed tissue specifically. This review highlights functions of ADAMs in the mammalian nervous system, including their links to diseases. The non-proteolytic ADAM11, ADAM22 and ADAM23 have key functions in neural development, myelination and synaptic transmission and are linked to epilepsy. Among the proteolytic ADAMs, ADAM10 is the best characterized one due to its substrates Notch and amyloid precursor protein, where cleavage is required for nervous system development or linked to Alzheimer's disease (AD), respectively. Recent work demonstrates that ADAM10 has additional substrates and functions in the nervous system and its substrate selectivity may be regulated by tetraspanins. New roles for other proteolytic ADAMs in the nervous system are also emerging. For example, ADAM8 and ADAM17 are involved in neuroinflammation. ADAM17 additionally regulates neurite outgrowth and myelination and its activity is controlled by iRhoms. ADAM19 and ADAM21 function in regenerative processes upon neuronal injury. Several ADAMs, including ADAM9, ADAM10, ADAM15 and ADAM30, are potential drug targets for AD. Taken together, this review summarizes recent progress concerning substrates and functions of ADAMs in the nervous system and their use as drug targets for neurological and psychiatric diseases.

Entities:  

Keywords:  ADAM; Ectodomain shedding; Metalloprotease; Neural development; Neurological disease

Mesh:

Substances:

Year:  2019        PMID: 31236626     DOI: 10.1007/s00018-019-03173-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  30 in total

Review 1.  Metalloproteinases in nervous system function and pathology: introduction.

Authors:  Santiago Rivera
Journal:  Cell Mol Life Sci       Date:  2019-06-07       Impact factor: 9.261

Review 2.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

3.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

4.  Quantitative Proteomics Reveals That ADAM15 Can Have Proteolytic-Independent Functions in the Steady State.

Authors:  Chun-Yao Yang; Simone Bonelli; Matteo Calligaris; Anna Paola Carreca; Stephan A Müller; Stefan F Lichtenthaler; Linda Troeberg; Simone D Scilabra
Journal:  Membranes (Basel)       Date:  2022-05-31

5.  The effect of extrinsic Wnt/β-catenin signaling in Muller glia on retinal ganglion cell neurite growth.

Authors:  Ganeswara Rao Musada; Galina Dvoriantchikova; Ciara Myer; Dmitry Ivanov; Sanjoy K Bhattacharya; Abigail S Hackam
Journal:  Dev Neurobiol       Date:  2020-04-17       Impact factor: 3.964

Review 6.  New insights into the molecular mechanisms of axon guidance receptor regulation and signaling.

Authors:  Yixin Zang; Karina Chaudhari; Greg J Bashaw
Journal:  Curr Top Dev Biol       Date:  2021-01-18       Impact factor: 4.897

7.  Pharmacologic Inhibition of ADAM10 Attenuates Brain Tissue Loss, Axonal Injury and Pro-inflammatory Gene Expression Following Traumatic Brain Injury in Mice.

Authors:  Dominik Appel; Regina Hummel; Martin Weidemeier; Kristina Endres; Christina Gölz; Michael K E Schäfer
Journal:  Front Cell Dev Biol       Date:  2021-03-15

8.  ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion.

Authors:  Georg Jocher; Vincent Grass; Andreas Pichlmair; Stefan F Lichtenthaler; Sarah K Tschirner; Lydia Riepler; Stephan Breimann; Tuğberk Kaya; Madlen Oelsner; M Sabri Hamad; Laura I Hofmann; Carl P Blobel; Carsten B Schmidt-Weber; Ozgun Gokce; Constanze A Jakwerth; Jakob Trimpert; Janine Kimpel
Journal:  EMBO Rep       Date:  2022-05-08       Impact factor: 9.071

9.  Constitutive and Regulated Shedding of Soluble FGF Receptors Releases Biologically Active Inhibitors of FGF-2.

Authors:  Anne Hanneken; Maluz Mercado; Pamela Maher
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

Review 10.  Targeting ADAM10 in Cancer and Autoimmunity.

Authors:  Timothy M Smith; Anuj Tharakan; Rebecca K Martin
Journal:  Front Immunol       Date:  2020-03-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.